Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
2상
완료
NCT04159415
| 대상 질환 | Generalized Lipodystrophy |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Regeneron Pharmaceuticals |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 16 명 |
|---|
| 중재(약물) | Low-Dose REGN4461, High-dose REGN4461 |
|---|
| 시작일 | 2020년 1월 7일 |
|---|
| 완료일 | 2022년 1월 5일 |
|---|
| 결과 공개일 | 2025년 2월 25일 |
|---|
요약
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride levels in the subset of patients with elevated baseline fasting triglycerides (TG ≥250 mg/dL). The secondary objectives are to estimate the effects of REGN4461 on a composite endpoint of changes in either HbA1c or fasting TG for all patients, estimate the effects of 3 dose levels of REGN4461 on glycemic parameters and fasting TG, to estimate the effects of REGN4461 on insulin sensitivity, to evaluate the safety and tolerability of REGN4461 and to evaluate the pharmacokinetics (PK) and immunogenicity of REGN4461.
Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8
Baseline, Week 8 · millimoles per mole (mmol/mol)
| Treatment Sequence A, DBTP 1: Placebo SC QW | -0.1 ± 0.6 millimoles per mole (mmol/mol) |
|---|
| Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW | 0.2 ± 0.7 millimoles per mole (mmol/mol) |
|---|
| Least Squares (LS) Mean Difference | 0.2 (95% CI -1.9–2.3) |
|---|
Absolute Change From Baseline in Fasting Glucose at Week 8
Baseline, Week 8 · milligrams per deciliter (mg/dL)
| Treatment Sequence A, DBTP 1: Placebo SC QW | 15.5 ± 18.6 milligrams per deciliter (mg/dL) |
|---|
| Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW | 53.6 ± 19.9 milligrams per deciliter (mg/dL) |
|---|
| LS Mean Difference | 38.1 (95% CI -21.3–97.5) |
|---|
Absolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8
Baseline, Week 8 · mg/dL
| Treatment Sequence A, DBTP 1: Placebo SC QW | -3.7 ± 19.9 mg/dL |
|---|
| Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW | -3.7 ± 23.4 mg/dL |
|---|
| Adjusted Mean Difference | 0.0 (95% CI -56.9–56.9) |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.